Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 4, 2023, Novavax, Inc. (Nasdaq: NVAX) announced its participation in the World Vaccine Congress (WVC) and the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The company will showcase data on its COVID-19 prototype vaccine as a booster and its COVID-Influenza Combination (CIC) vaccine. Key presentations include insights on vaccine hesitancy and safety surveillance, scheduled from April 3 to 6 in Washington, DC, and April 15 to 18 in Copenhagen, Denmark. Novavax is also a finalist for the 2023 World Vaccine Congress Vaccine Industry Excellence Awards in two categories, with winners announced on April 4.
Novavax (Nasdaq: NVAX), a leader in protein-based vaccines, announced its participation in the TD Cowen's 43rd Annual Health Care Conference on March 8, 2023, from 9:50 – 10:20 a.m. EST. The conference will take place at the Boston Marriott Copley Place. John Trizzino, Chief Commercial Officer, will represent the company during a fireside chat moderated by Georgi Yordanov, an Equity Research Analyst in Biotechnology. A replay of the session will be accessible on Novavax's website for 90 days post-conference.
On March 2, 2023, Novavax announced the grant of stock options and restricted stock units to Elaine O'Hara, the newly appointed Chief Strategy Officer, effective March 1, 2023. The awards include a non-qualified stock option for 67,900 shares at an exercise price of $6.86, which vests over four years, and restricted stock units for 58,800 shares that vest over three years. These grants were made under the Novavax 2023 Inducement Plan and were approved to incentivize O'Hara's employment with the company. As a global leader in protein-based vaccines, Novavax continues to focus on developing key vaccines including those for COVID-19 and influenza.
Novavax, Inc. (Nasdaq: NVAX) reported fourth-quarter 2022 revenues of $357 million, a 61% increase year-over-year, and full-year revenues of $2.0 billion, reflecting 73% growth. The company updated its agreement with the U.S. government for an additional 1.5 million COVID-19 vaccine doses in 2023. Significant developments include the expansion of the Nuvaxovid™ label and initiation of a Phase 2 trial for a COVID-19-Influenza Combination vaccine. Despite a net loss of $182 million in Q4, down from $846 million in Q4 2021, cash reserves stand at $1.3 billion as of year-end 2022. Novavax aims to enhance efficiency and drive long-term value amid ongoing uncertainties.
Novavax, Inc. (NASDAQ: NVAX) will release its fourth quarter and full-year 2022 financial results on February 28, 2023, at 4:30 p.m. EST. The call will discuss operational highlights and include a Q&A session. Participants are encouraged to join early and can access the call through a webcast. A replay will be available from 7:30 p.m. EST on the same day until March 7, 2023. Novavax focuses on developing innovative vaccines for serious infectious diseases, enhancing vaccine efficacy through its patented Matrix-M adjuvant technology.
Novavax, Inc. (Nasdaq: NVAX) announced the extension of its agreement with the U.S. Department of Health and Human Services, securing up to 1.5 million doses of its COVID-19 vaccine, NVX-CoV2373. The modified agreement aims to enhance public access to the vaccine and includes plans for smaller dose vials and strain selection aligned with FDA guidance. The partnership highlights the importance of Novavax's protein-based vaccine in the U.S. COVID-19 vaccination campaign for 2023/2024. The vaccine is authorized for emergency use, primarily for individuals aged 12 and over, and will be provided free to states and healthcare partners.